Drugs / SKG0106
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06237777 | May 2024 → Jan 2026 | diabetic macular edema | Wang Min | Unknown | No outcome recorded |
| Phase 1 | NCT06213038 | May 2023 → May 2025 overdue | wet macular degeneration | Youxin Chen | Recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05986864 | Feb 2024 → Jan 2026 overdue | wet macular degeneration | Skyline Therapeutics | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SKG0106 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06237777 ↗ |
| Modality | Gene therapy (AAV / viral vector) | “SKG0106 is a recombinant adeno-associated virus (AAV) vector-based in vivo gene therapeutic product” NCT05986864 ↗ |
| Route | Intravitreal | “SKG0106 Intravitreal Injection” NCT05986864 ↗ |